Novartis, Pfizer to co-market Exforge in October

Published: 2007-09-10 07:00:00

Updated: 2007-09-10 07:00:00

Novartis Korea and Pfizer Korea said on September 6 that they will begin the co-marketing of Exforge, a combined formulation of amlodipine, a dihydropyridine calcium-channel blocker, and valsartan, an angiotensin II receptor antagonist in October through mutual agreement on August 30.

This ora...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK